Date:11/7/2012

ross profit excludes certain specified items, as indicated in the previous footnote.Hospira, Inc.Condensed Consolidated Statements of Income(Unaudited)(dollars and shares in millions, except for per share amounts)Nine Months Ended September 30,% Change20122011Net sales$
2,993.2$
3,043.1(1.6)%Cost of products sold2,195.41,926.713.9%Restructuring, impairment and (gain) on disposition of assets, net41.6184.9(77.5)%Research and development218.9192.014.0%Selling, general and administrative509.3470.48.3%Total operating costs and expenses2,965.22,774.06.9%Income From Operations28.0269.1(89.6)%Interest expense64.370.7(9.1)%Other expense (income), net12.8(6.0)313.3%(Loss) Income Before Income Taxes(49.1)204.4(124.0)%Income tax (benefit) expense(61.0)38.0(260.5)%Equity income from affiliates, net(27.0)(38.2)(29.3)%Net Income$
38.9$
204.6(81.0)%Earnings Per Common Share:Basic$
.24$
.23(80.5)%Diluted$
.23$
.21(81.0)%Weighted Average Common Shares Outstanding:Basic165.0165.8(0.5)%Diluted166.0168.7(1.6)%Adjusted Gross Profit (1)(2)$
,062.3$
,219.0(12.9)%Adjusted Income From Operations (1)$
334.1$
557.8(40.1)%Adjusted Net Income (1)$
242.0$
425.3(43.1)%Adjusted Diluted Earnings Per Share (1)$
.46$
2.52(42.1)%Statistics (as a % of net sales, except for income tax rate):GAAP Nine Months Ended September 30,Adjusted (1) Nine Months Ended September 30,2012201120122011Gross Profit (2)

26.7%36.7%35.5%40.1%Income From Operations

0.9%8.8%11.2%18.3%Net Income1.3%6.7%8.1%14.0%Income Tax Rate

124.2%18.6%19.0%21.5%(1)

Adjusted financial measures exclude certain specified items as described and reconciled to comparable GAAP financial measures in the Reconciliation of GAAP to Non-GAAP Financial Measures contained in this press release.(2)

Gross profit is defined as Net sales less Cost of products sold. Adjusted gross profit excludes certain specified items,
'/>"/>

SOURCE Hospira, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.